Fidelity Investments
ARTV

Fidelity Investments’s Artiva Biotherapeutics ARTV Stock Holding History

Fidelity Investments’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.7K Sell
3,529
-29
-0.8% -$143 ﹤0.01% 4460
2025
Q4 		$15.3K Sell
3,558
-1,362
-28% -$5.14K ﹤0.01% 4579
2025
Q3 		$14.1K Sell
4,920
-37,357
-88% -$100K ﹤0.01% 4499
2025
Q2 		$63.8K Buy
42,277
+38,722
+1,089% +$81.3K ﹤0.01% 3784
2025
Q1 		$10.7K Buy
3,555
+2,655
+295% +$14.3K ﹤0.01% 4475
2024
Q4 		$9.07K Buy
900
+740
+463% +$8.89K ﹤0.01% 4493
2024
Q3 		$2.47K Buy
+160
New +$1.85K ﹤0.01% 4762

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Fidelity Investments's ARTV Position: Q1 2026 in Review

Fidelity Investments reduced its Artiva Biotherapeutics (ARTV) stake by 0.82% in Q1 2026, selling an estimated $143 and leaving 3,529 shares worth $22.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4460.

Fidelity Investments first reported a position in ARTV in Q3 2024 and has held it in 7 quarters since. The position peaked at $63.8K in Q2 2025. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • Fidelity Investments held 3,529 shares of Artiva Biotherapeutics worth $22.7K as of Q1 2026.
  • Fidelity Investments sold 29 Artiva Biotherapeutics shares in Q1 2026, an estimated $143.
  • Artiva Biotherapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #4460 holding.
  • Fidelity Investments first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 7 quarters since.
  • Fidelity Investments's Artiva Biotherapeutics position peaked at $63.8K in Q2 2025.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.